Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: March 2012

“It’s not junk”–RaNA Therapeutics emerges from stealth mode with $20.7 million in venture funding-Part 2

Tweet  This is Part 2 of the article on RaNA Therapeutics that we began on March 29, 2012. Jeannie Lee’s research and RaNA’s technology platform Jeannie Lee’s laboratory focuses on the study of the mechanism of X-chromosome inactivation in mammals. In X-chromosome inactivation, one of the two copies of the X chromosome present in the…

“It’s not junk”–RaNA Therapeutics emerges from stealth mode with $20.7 million in venture funding-Part 1

Tweet    On January 18, 2012, start-up company RaNA Therapeutics (Cambridge, MA) emerged from stealth mode with 20.7 million in cash. The Series A venture funding was co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. RaNA will work on developing a technology platform that involves targeting long noncoding RNA…

The Biopharmconsortium Blog hiatus to end soon!

Tweet  As you all may have noticed, we have not had a post on the Biopharmconsortium Blog during the entire month of February, 2012. This unintended hiatus happened because of the need to finish up other work. We’re almost finished with these projects, and have several ideas for blog articles (including some articles that we…